Department of Cardiology and Pneumology, Innovative Clinical Trials, University Medical Center Goettingen, Goettingen, Germany.
J Cachexia Sarcopenia Muscle. 2018 Feb;9(1):176-182. doi: 10.1002/jcsm.12290.
This article highlights the updates from preclinical and clinical studies into the field of wasting disorders that were presented at the 10th Cachexia Conference held in Rome, Italy, in December 2017. This year's conference saw some interesting results of larger-scale studies and clinical trials and new therapeutic targets. Herein, we summarize the biological and clinical significance of different markers and new diagnostic tools and cut-offs for the detection of skeletal muscle wasting, including micro RNAs, the ubiquitin-proteasome system, mTOR signalling, news in body composition analysis including the D3-creatine dilution method, and new biomarkers. Clinical studies investigated novel nutritional approaches, trials of elamipretide, enobosarm, and urolithin A. It remains a fact, however, that effective treatments of cachexia and wasting disorders are urgently needed in order to improve patients' quality of life and their survival.
本文重点介绍了 2017 年 12 月在意大利罗马举行的第十届恶病质会议上展示的有关消耗性疾病的临床前和临床研究的最新进展。今年的会议上，一些较大规模的研究和临床试验取得了一些有趣的结果，并确定了新的治疗靶点。在这里，我们总结了不同标记物和新的诊断工具的生物学和临床意义，以及用于检测骨骼肌消耗的新的诊断截止值，包括 microRNAs、泛素蛋白酶体系统、mTOR 信号通路、包括 D3-肌酸稀释法在内的身体成分分析的新方法，以及新的生物标志物。临床研究还调查了新型营养方法、elamipretide、enobosarm 和 urolithin A 的试验。然而，事实上，为了提高患者的生活质量和生存，迫切需要有效的恶病质和消耗性疾病的治疗方法。
